title: Preliminary results of intensity-modulated radiation therapy with helical tomotherapy for prostate cancer.
abstract: OBJECTIVE
  We present the preliminary results of intensity-modulated radiation therapy with helical tomotherapy (HT) for clinically localized prostate cancer.
  
  
  METHODS
  Regularly followed 241 consecutive patients, who were treated with HT between June 2006 and December 2010, were included in this retrospective study. Most patients received both relatively long-term neoadjuvant and adjuvant androgen deprivation therapy (ADT). Patients received 78 Gy in the intermediate high-risk group and 74 Gy in the low-risk group. Biochemical disease-free survival (bDFS) followed the Phoenix definition. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading scale.
  
  
  RESULTS
  The median follow-up time from the start date of HT was 35 months. The rates of acute Grade 2 gastro-intestinal (GI) and genitor-urinary (GU) toxicities were 11.2 and 24.5 %. No patients experienced acute Grade 3 or higher symptoms. The rates of late Grade 2 and 3 GI toxicities were 6.6 and 0.8 %, and those of late Grade 2 and 3 GU toxicities were 8.3 % and 1.2 %. No patients experienced late Grade 4 toxicity. The 3-year bDFS rates for low, intermediate, and high-risk group patients were 100, 100, and 95.8 %, respectively. We observed clinical relapse in two high-risk patients, resulting in a 3-year clinical DFS of 99.4 %.
  
  
  CONCLUSIONS
  This preliminary report confirms the feasibility of HT in a large number of patients. We observed that HT is associated with low rates of acute and late toxicities, and HT in combination with relatively long-term ADT results in excellent short-term bDFS.
authors: Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusaku, Nagoya 464-8681, Japan. ntomita@aichi-cc.jp
authors: Natsuo
authors: N
authors: Tomita
authors: Norihito
authors: N
authors: Soga
authors: Yuji
authors: Y
authors: Ogura
authors: Norio
authors: N
authors: Hayashi
authors: Hidetoshi
authors: H
authors: Shimizu
authors: Takashi
authors: T
authors: Kubota
authors: Junji
authors: J
authors: Ito
authors: Kimiko
authors: K
authors: Hirata
authors: Yukihiko
authors: Y
authors: Ohshima
authors: Hiroyuki
authors: H
authors: Tachibana
authors: Takeshi
authors: T
authors: Kodaira
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D059248:Chemoradiotherapy / Q000009:adverse effects; D018572:Disease-Free Survival; D005767:Gastrointestinal Diseases / Q000209:etiology; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases / Q000209:etiology; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011467:Prostate / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000534:rehabilitation*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists